nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Epirubicin—pancreatic cancer	0.183	0.311	CbGbCtD
Zoledronate—ABCC1—Irinotecan—pancreatic cancer	0.178	0.302	CbGbCtD
Zoledronate—ABCC1—Docetaxel—pancreatic cancer	0.131	0.222	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—pancreatic cancer	0.0973	0.165	CbGbCtD
Zoledronate—Risedronate—PTGS2—pancreatic cancer	0.00173	0.529	CrCbGaD
Zoledronate—Clodronate—PTGS2—pancreatic cancer	0.00154	0.471	CrCbGaD
Zoledronate—Hypersensitivity—Irinotecan—pancreatic cancer	0.000219	0.000537	CcSEcCtD
Zoledronate—Convulsion—Docetaxel—pancreatic cancer	0.000218	0.000535	CcSEcCtD
Zoledronate—Hypertension—Docetaxel—pancreatic cancer	0.000217	0.000533	CcSEcCtD
Zoledronate—Infestation NOS—Epirubicin—pancreatic cancer	0.000217	0.000533	CcSEcCtD
Zoledronate—Infestation—Epirubicin—pancreatic cancer	0.000217	0.000533	CcSEcCtD
Zoledronate—Arthralgia—Docetaxel—pancreatic cancer	0.000214	0.000526	CcSEcCtD
Zoledronate—Myalgia—Docetaxel—pancreatic cancer	0.000214	0.000526	CcSEcCtD
Zoledronate—Chest pain—Docetaxel—pancreatic cancer	0.000214	0.000526	CcSEcCtD
Zoledronate—Nausea—Sunitinib—pancreatic cancer	0.000214	0.000526	CcSEcCtD
Zoledronate—Pancytopenia—Doxorubicin—pancreatic cancer	0.000214	0.000525	CcSEcCtD
Zoledronate—Renal failure—Epirubicin—pancreatic cancer	0.000214	0.000524	CcSEcCtD
Zoledronate—Asthenia—Irinotecan—pancreatic cancer	0.000213	0.000523	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000213	0.000522	CcSEcCtD
Zoledronate—Stomatitis—Epirubicin—pancreatic cancer	0.000212	0.00052	CcSEcCtD
Zoledronate—Urinary tract infection—Epirubicin—pancreatic cancer	0.000211	0.000518	CcSEcCtD
Zoledronate—Conjunctivitis—Epirubicin—pancreatic cancer	0.000211	0.000518	CcSEcCtD
Zoledronate—Neutropenia—Doxorubicin—pancreatic cancer	0.000211	0.000517	CcSEcCtD
Zoledronate—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00021	0.000515	CcSEcCtD
Zoledronate—Dry mouth—Docetaxel—pancreatic cancer	0.00021	0.000514	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000209	0.000514	CcSEcCtD
Zoledronate—Pollakiuria—Doxorubicin—pancreatic cancer	0.000208	0.000511	CcSEcCtD
Zoledronate—Asthenia—Gemcitabine—pancreatic cancer	0.000208	0.00051	CcSEcCtD
Zoledronate—Haematuria—Epirubicin—pancreatic cancer	0.000207	0.000508	CcSEcCtD
Zoledronate—Confusional state—Docetaxel—pancreatic cancer	0.000207	0.000508	CcSEcCtD
Zoledronate—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000205	0.000504	CcSEcCtD
Zoledronate—Oedema—Docetaxel—pancreatic cancer	0.000205	0.000504	CcSEcCtD
Zoledronate—Weight increased—Doxorubicin—pancreatic cancer	0.000205	0.000503	CcSEcCtD
Zoledronate—Pruritus—Gemcitabine—pancreatic cancer	0.000205	0.000503	CcSEcCtD
Zoledronate—Infection—Docetaxel—pancreatic cancer	0.000204	0.000501	CcSEcCtD
Zoledronate—Weight decreased—Doxorubicin—pancreatic cancer	0.000204	0.0005	CcSEcCtD
Zoledronate—Diarrhoea—Irinotecan—pancreatic cancer	0.000203	0.000499	CcSEcCtD
Zoledronate—Agranulocytosis—Epirubicin—pancreatic cancer	0.000203	0.000497	CcSEcCtD
Zoledronate—Shock—Docetaxel—pancreatic cancer	0.000202	0.000496	CcSEcCtD
Zoledronate—Nervous system disorder—Docetaxel—pancreatic cancer	0.000201	0.000494	CcSEcCtD
Zoledronate—Pruritus—Fluorouracil—pancreatic cancer	0.000201	0.000494	CcSEcCtD
Zoledronate—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000201	0.000494	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—pancreatic cancer	0.000201	0.000493	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—pancreatic cancer	0.000201	0.000493	CcSEcCtD
Zoledronate—Tachycardia—Docetaxel—pancreatic cancer	0.0002	0.000492	CcSEcCtD
Zoledronate—Skin disorder—Docetaxel—pancreatic cancer	0.000199	0.00049	CcSEcCtD
Zoledronate—Bradycardia—Epirubicin—pancreatic cancer	0.000198	0.000487	CcSEcCtD
Zoledronate—Diarrhoea—Gemcitabine—pancreatic cancer	0.000198	0.000486	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—pancreatic cancer	0.000198	0.000485	CcSEcCtD
Zoledronate—Dizziness—Irinotecan—pancreatic cancer	0.000196	0.000482	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—pancreatic cancer	0.000196	0.000481	CcSEcCtD
Zoledronate—Anorexia—Docetaxel—pancreatic cancer	0.000196	0.00048	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000195	0.000479	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000195	0.000479	CcSEcCtD
Zoledronate—Diarrhoea—Fluorouracil—pancreatic cancer	0.000195	0.000478	CcSEcCtD
Zoledronate—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000194	0.000476	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000193	0.000473	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—pancreatic cancer	0.000192	0.000471	CcSEcCtD
Zoledronate—Hypotension—Docetaxel—pancreatic cancer	0.000192	0.000471	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—pancreatic cancer	0.000192	0.00047	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000192	0.00047	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—pancreatic cancer	0.000191	0.000469	CcSEcCtD
Zoledronate—Vomiting—Irinotecan—pancreatic cancer	0.000189	0.000464	CcSEcCtD
Zoledronate—Dizziness—Fluorouracil—pancreatic cancer	0.000188	0.000462	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000188	0.00046	CcSEcCtD
Zoledronate—Rash—Irinotecan—pancreatic cancer	0.000187	0.00046	CcSEcCtD
Zoledronate—Dermatitis—Irinotecan—pancreatic cancer	0.000187	0.000459	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000187	0.000459	CcSEcCtD
Zoledronate—Headache—Irinotecan—pancreatic cancer	0.000186	0.000457	CcSEcCtD
Zoledronate—Insomnia—Docetaxel—pancreatic cancer	0.000186	0.000456	CcSEcCtD
Zoledronate—Paraesthesia—Docetaxel—pancreatic cancer	0.000184	0.000453	CcSEcCtD
Zoledronate—Vomiting—Gemcitabine—pancreatic cancer	0.000184	0.000452	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—pancreatic cancer	0.000184	0.000451	CcSEcCtD
Zoledronate—Dyspnoea—Docetaxel—pancreatic cancer	0.000183	0.000449	CcSEcCtD
Zoledronate—Somnolence—Docetaxel—pancreatic cancer	0.000183	0.000448	CcSEcCtD
Zoledronate—Rash—Gemcitabine—pancreatic cancer	0.000182	0.000448	CcSEcCtD
Zoledronate—Dermatitis—Gemcitabine—pancreatic cancer	0.000182	0.000447	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—pancreatic cancer	0.000182	0.000447	CcSEcCtD
Zoledronate—Headache—Gemcitabine—pancreatic cancer	0.000181	0.000445	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—pancreatic cancer	0.000181	0.000444	CcSEcCtD
Zoledronate—Flushing—Epirubicin—pancreatic cancer	0.000181	0.000444	CcSEcCtD
Zoledronate—Vomiting—Fluorouracil—pancreatic cancer	0.000181	0.000444	CcSEcCtD
Zoledronate—Dyspepsia—Docetaxel—pancreatic cancer	0.000181	0.000444	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00018	0.000441	CcSEcCtD
Zoledronate—Rash—Fluorouracil—pancreatic cancer	0.000179	0.00044	CcSEcCtD
Zoledronate—Dermatitis—Fluorouracil—pancreatic cancer	0.000179	0.00044	CcSEcCtD
Zoledronate—Decreased appetite—Docetaxel—pancreatic cancer	0.000179	0.000438	CcSEcCtD
Zoledronate—Headache—Fluorouracil—pancreatic cancer	0.000178	0.000438	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000178	0.000437	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000178	0.000436	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000177	0.000435	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000177	0.000435	CcSEcCtD
Zoledronate—Fatigue—Docetaxel—pancreatic cancer	0.000177	0.000435	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—pancreatic cancer	0.000177	0.000434	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—pancreatic cancer	0.000177	0.000434	CcSEcCtD
Zoledronate—Nausea—Irinotecan—pancreatic cancer	0.000176	0.000433	CcSEcCtD
Zoledronate—Immune system disorder—Epirubicin—pancreatic cancer	0.000176	0.000432	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000176	0.000431	CcSEcCtD
Zoledronate—Pain—Docetaxel—pancreatic cancer	0.000176	0.000431	CcSEcCtD
Zoledronate—Constipation—Docetaxel—pancreatic cancer	0.000176	0.000431	CcSEcCtD
Zoledronate—Chills—Epirubicin—pancreatic cancer	0.000175	0.000429	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—pancreatic cancer	0.000174	0.000428	CcSEcCtD
Zoledronate—Alopecia—Epirubicin—pancreatic cancer	0.000172	0.000423	CcSEcCtD
Zoledronate—Nausea—Gemcitabine—pancreatic cancer	0.000172	0.000422	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—pancreatic cancer	0.000171	0.000419	CcSEcCtD
Zoledronate—Malnutrition—Epirubicin—pancreatic cancer	0.00017	0.000417	CcSEcCtD
Zoledronate—Erythema—Epirubicin—pancreatic cancer	0.00017	0.000417	CcSEcCtD
Zoledronate—Feeling abnormal—Docetaxel—pancreatic cancer	0.000169	0.000415	CcSEcCtD
Zoledronate—Nausea—Fluorouracil—pancreatic cancer	0.000169	0.000415	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—pancreatic cancer	0.000169	0.000414	CcSEcCtD
Zoledronate—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000168	0.000412	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000167	0.000411	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—pancreatic cancer	0.000167	0.000411	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—pancreatic cancer	0.000166	0.000408	CcSEcCtD
Zoledronate—Back pain—Epirubicin—pancreatic cancer	0.000164	0.000403	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—pancreatic cancer	0.000164	0.000402	CcSEcCtD
Zoledronate—Muscle spasms—Epirubicin—pancreatic cancer	0.000163	0.000401	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—pancreatic cancer	0.000163	0.0004	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000163	0.000399	CcSEcCtD
Zoledronate—Abdominal pain—Docetaxel—pancreatic cancer	0.000162	0.000398	CcSEcCtD
Zoledronate—Body temperature increased—Docetaxel—pancreatic cancer	0.000162	0.000398	CcSEcCtD
Zoledronate—Chills—Doxorubicin—pancreatic cancer	0.000162	0.000397	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—pancreatic cancer	0.000161	0.000396	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—pancreatic cancer	0.00016	0.000393	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—pancreatic cancer	0.000159	0.000391	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—pancreatic cancer	0.000158	0.000388	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000157	0.000387	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—pancreatic cancer	0.000157	0.000385	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—pancreatic cancer	0.000157	0.000385	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—pancreatic cancer	0.000157	0.000385	CcSEcCtD
Zoledronate—Agitation—Epirubicin—pancreatic cancer	0.000156	0.000383	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—pancreatic cancer	0.000154	0.000377	CcSEcCtD
Zoledronate—Malaise—Epirubicin—pancreatic cancer	0.000153	0.000376	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—pancreatic cancer	0.000152	0.000374	CcSEcCtD
Zoledronate—Syncope—Epirubicin—pancreatic cancer	0.000152	0.000374	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—pancreatic cancer	0.000152	0.000373	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—pancreatic cancer	0.000152	0.000373	CcSEcCtD
Zoledronate—Hypersensitivity—Docetaxel—pancreatic cancer	0.000151	0.000371	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—pancreatic cancer	0.000151	0.000371	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—pancreatic cancer	0.00015	0.000368	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—pancreatic cancer	0.000149	0.000366	CcSEcCtD
Zoledronate—Cough—Epirubicin—pancreatic cancer	0.000148	0.000364	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—pancreatic cancer	0.000148	0.000363	CcSEcCtD
Zoledronate—Asthenia—Docetaxel—pancreatic cancer	0.000147	0.000362	CcSEcCtD
Zoledronate—Convulsion—Epirubicin—pancreatic cancer	0.000147	0.000361	CcSEcCtD
Zoledronate—Hypertension—Epirubicin—pancreatic cancer	0.000147	0.00036	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000146	0.000358	CcSEcCtD
Zoledronate—Pruritus—Docetaxel—pancreatic cancer	0.000145	0.000357	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—pancreatic cancer	0.000145	0.000356	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—pancreatic cancer	0.000145	0.000355	CcSEcCtD
Zoledronate—Arthralgia—Epirubicin—pancreatic cancer	0.000145	0.000355	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—pancreatic cancer	0.000145	0.000355	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—pancreatic cancer	0.000144	0.000354	CcSEcCtD
Zoledronate—Anxiety—Epirubicin—pancreatic cancer	0.000144	0.000353	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000144	0.000352	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—pancreatic cancer	0.000143	0.00035	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—pancreatic cancer	0.000142	0.000348	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—pancreatic cancer	0.000141	0.000347	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—pancreatic cancer	0.000141	0.000346	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—pancreatic cancer	0.000141	0.000346	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—pancreatic cancer	0.000141	0.000345	CcSEcCtD
Zoledronate—Diarrhoea—Docetaxel—pancreatic cancer	0.000141	0.000345	CcSEcCtD
Zoledronate—Confusional state—Epirubicin—pancreatic cancer	0.00014	0.000343	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—pancreatic cancer	0.000139	0.000341	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000139	0.00034	CcSEcCtD
Zoledronate—Oedema—Epirubicin—pancreatic cancer	0.000139	0.00034	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000138	0.000339	CcSEcCtD
Zoledronate—Infection—Epirubicin—pancreatic cancer	0.000138	0.000338	CcSEcCtD
Zoledronate—Cough—Doxorubicin—pancreatic cancer	0.000137	0.000336	CcSEcCtD
Zoledronate—Shock—Epirubicin—pancreatic cancer	0.000136	0.000335	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—pancreatic cancer	0.000136	0.000334	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—pancreatic cancer	0.000136	0.000333	CcSEcCtD
Zoledronate—Dizziness—Docetaxel—pancreatic cancer	0.000136	0.000333	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000136	0.000333	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—pancreatic cancer	0.000136	0.000333	CcSEcCtD
Zoledronate—Tachycardia—Epirubicin—pancreatic cancer	0.000135	0.000332	CcSEcCtD
Zoledronate—Skin disorder—Epirubicin—pancreatic cancer	0.000135	0.00033	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000134	0.000329	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—pancreatic cancer	0.000134	0.000328	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—pancreatic cancer	0.000134	0.000328	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—pancreatic cancer	0.000134	0.000328	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—pancreatic cancer	0.000133	0.000327	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000133	0.000326	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—pancreatic cancer	0.000132	0.000324	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—pancreatic cancer	0.000132	0.000324	CcSEcCtD
Zoledronate—Dry mouth—Doxorubicin—pancreatic cancer	0.000131	0.000321	CcSEcCtD
Zoledronate—Vomiting—Docetaxel—pancreatic cancer	0.000131	0.00032	CcSEcCtD
Zoledronate—Rash—Docetaxel—pancreatic cancer	0.000129	0.000318	CcSEcCtD
Zoledronate—Hypotension—Epirubicin—pancreatic cancer	0.000129	0.000318	CcSEcCtD
Zoledronate—Dermatitis—Docetaxel—pancreatic cancer	0.000129	0.000318	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—pancreatic cancer	0.000129	0.000317	CcSEcCtD
Zoledronate—Headache—Docetaxel—pancreatic cancer	0.000129	0.000316	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000128	0.000315	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—pancreatic cancer	0.000128	0.000315	CcSEcCtD
Zoledronate—Infection—Doxorubicin—pancreatic cancer	0.000127	0.000313	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000126	0.00031	CcSEcCtD
Zoledronate—Shock—Doxorubicin—pancreatic cancer	0.000126	0.00031	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000126	0.000309	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000125	0.000308	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—pancreatic cancer	0.000125	0.000308	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—pancreatic cancer	0.000125	0.000307	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—pancreatic cancer	0.000124	0.000306	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—pancreatic cancer	0.000124	0.000305	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000124	0.000304	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—pancreatic cancer	0.000124	0.000303	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—pancreatic cancer	0.000123	0.000302	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—pancreatic cancer	0.000122	0.0003	CcSEcCtD
Zoledronate—Nausea—Docetaxel—pancreatic cancer	0.000122	0.000299	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—pancreatic cancer	0.000122	0.000299	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—pancreatic cancer	0.00012	0.000296	CcSEcCtD
Zoledronate—Hypotension—Doxorubicin—pancreatic cancer	0.00012	0.000294	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00012	0.000294	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—pancreatic cancer	0.000119	0.000293	CcSEcCtD
Zoledronate—Constipation—Epirubicin—pancreatic cancer	0.000118	0.000291	CcSEcCtD
Zoledronate—Pain—Epirubicin—pancreatic cancer	0.000118	0.000291	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000117	0.000287	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—pancreatic cancer	0.000116	0.000285	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—pancreatic cancer	0.000115	0.000282	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—pancreatic cancer	0.000114	0.00028	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—pancreatic cancer	0.000114	0.00028	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—pancreatic cancer	0.000114	0.00028	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000113	0.000278	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—pancreatic cancer	0.000113	0.000277	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—pancreatic cancer	0.000111	0.000273	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000111	0.000272	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—pancreatic cancer	0.000111	0.000271	CcSEcCtD
Zoledronate—Urticaria—Epirubicin—pancreatic cancer	0.00011	0.00027	CcSEcCtD
Zoledronate—Pain—Doxorubicin—pancreatic cancer	0.00011	0.000269	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—pancreatic cancer	0.00011	0.000269	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—pancreatic cancer	0.00011	0.000269	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—pancreatic cancer	0.00011	0.000269	CcSEcCtD
Zoledronate—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000106	0.000259	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000105	0.000257	CcSEcCtD
Zoledronate—Hypersensitivity—Epirubicin—pancreatic cancer	0.000102	0.00025	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—pancreatic cancer	0.000102	0.00025	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—pancreatic cancer	0.000101	0.000249	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—pancreatic cancer	0.000101	0.000249	CcSEcCtD
Zoledronate—Asthenia—Epirubicin—pancreatic cancer	9.94e-05	0.000244	CcSEcCtD
Zoledronate—Pruritus—Epirubicin—pancreatic cancer	9.8e-05	0.000241	CcSEcCtD
Zoledronate—Diarrhoea—Epirubicin—pancreatic cancer	9.48e-05	0.000233	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—pancreatic cancer	9.44e-05	0.000232	CcSEcCtD
Zoledronate—Asthenia—Doxorubicin—pancreatic cancer	9.2e-05	0.000226	CcSEcCtD
Zoledronate—Dizziness—Epirubicin—pancreatic cancer	9.16e-05	0.000225	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—pancreatic cancer	9.07e-05	0.000223	CcSEcCtD
Zoledronate—Vomiting—Epirubicin—pancreatic cancer	8.81e-05	0.000216	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—pancreatic cancer	8.77e-05	0.000215	CcSEcCtD
Zoledronate—Rash—Epirubicin—pancreatic cancer	8.73e-05	0.000214	CcSEcCtD
Zoledronate—Dermatitis—Epirubicin—pancreatic cancer	8.73e-05	0.000214	CcSEcCtD
Zoledronate—Headache—Epirubicin—pancreatic cancer	8.68e-05	0.000213	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—pancreatic cancer	8.48e-05	0.000208	CcSEcCtD
Zoledronate—Nausea—Epirubicin—pancreatic cancer	8.23e-05	0.000202	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—pancreatic cancer	8.15e-05	0.0002	CcSEcCtD
Zoledronate—Rash—Doxorubicin—pancreatic cancer	8.08e-05	0.000198	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—pancreatic cancer	8.07e-05	0.000198	CcSEcCtD
Zoledronate—Headache—Doxorubicin—pancreatic cancer	8.03e-05	0.000197	CcSEcCtD
Zoledronate—Nausea—Doxorubicin—pancreatic cancer	7.61e-05	0.000187	CcSEcCtD
